The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global recombinant DNA technology market reached a value of US$ XX Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
The advent of recombinant DNA technology has revolutionized development in biology and offered new opportunities for innovations. Also known as genetic engineering, it is currently widely used to alter genetic material outside an organism and obtain improved and desired characteristics in living organisms. It includes the insertion of DNA fragments from several sources that have a desirable gene sequence through an appropriate vector. Besides this, it assists in the safe, affordable, and sufficient production of vital proteins required for dietary purposes and fighting health problems. As a result, it has multidisciplinary applications and a remarkable potential to improve health and enhance food resources and resistance to divergent adverse environmental effects.
The recombinant DNA technology is utilized for improving different health conditions, mainly by developing new vaccines and pharmaceuticals. This, coupled with the improving treatment strategies on account of the developing diagnostics kits, monitoring devices, and new therapeutic approaches, represents one of the key factors impelling the growth of the market. Moreover, there is a rise in the research conducted on genetically modified organisms (GMO), which include microorganisms that are considered as bio degraders and clean fuel producers. This can be accredited to rapid urbanization, growing global population, reducing arable land, considerable rising food shortage and increasing adoption of GMO crops. Apart from this, as recombinant DNA technology offers several innovation opportunities to develop a vast range of therapeutic products with immediate effect in medical genetics and biomedicine, its application is expanding in various sectors. For instance, the integration of recombinant DNA technology with effective gene therapy for replacing the defective gene with normal ones and the production of antigen-specific antibodies for clinical research, studies, and disease diagnosis, are anticipated to drive the market growth in the upcoming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global recombinant DNA technology market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, component, application and end user.
Breakup by Product:
Breakup by Component:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc, Cibus, F.Hoffmann-La Roche Ltd, GenScript, GlaxoSmithKline plc., Horizon Discovery Group plc, Merck KGaA, New England Biolabs, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A and Syngene International Ltd (Biocon Limited).
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Component, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Amgen Inc, Cibus, F.Hoffmann-La Roche Ltd, GenScript, GlaxoSmithKline plc., Horizon Discovery Group plc, Merck KGaA, New England Biolabs, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A and Syngene International Ltd (Biocon Limited).|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at